Okla. Admin. Code § 310:550-1-1

Current through Vol. 42, No. 7, December 16, 2024
Section 310:550-1-1 - Purpose

Under 63 O.S., Sections 1-533 and 1-534 the following rules and regulations are established concerning the screening of all infants born in Oklahoma for the disorders of phenylketonuria, congenital hypothyroidism, galactosemia, sickle cell diseases, cystic fibrosis, congenital adrenal hyperplasia, medium-chain acyl coenzyme A dehydrogenase deficiency (MCAD), infants shall be screened for biotinidase deficiency, amino acid disorders, fatty acid oxidation disorders, organic acid disorders , and upon completion of laboratory validation studies and establishment of short-term follow-up services, Severe Combined Immunodeficiency (SCID) detectable via the Department's laboratory technology utilized in newborn screening and approved by the Commissioner of Health. This chapter establishes the following rules and regulations concerning screening all infants born at a birthing facility in Oklahoma for critical congenital heart disease (CCDH) via pulse oximetry screening performed by the birthing facility pursuant to 63 O.S. Section 1-550.5.

Okla. Admin. Code § 310:550-1-1

Amended at 9 Ok Reg 1475, eff 5-1-92; Amended at 21 Ok Reg 1286, eff 5-27-04; Amended at 25 Ok Reg 1151, eff 5-25-08; Amended at 25 Ok Reg 105, eff 10-2-07 (emergency); Amended at 25 Ok Reg 1153, eff 5-25-08
Amended by Oklahoma Register, Volume 31, Issue 24, September 2, 2014, eff. 9/12/2014